SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093296
Filing Date
2024-08-08
Accepted
2024-08-08 07:04:23
Documents
75
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q glue-20240630.htm   iXBRL 10-Q 1779627
2 EX-10.1 glue-ex10_1.htm EX-10.1 163910
3 EX-31.1 glue-ex31_1.htm EX-31.1 17168
4 EX-32.1 glue-ex32_1.htm EX-32.1 10069
  Complete submission text file 0000950170-24-093296.txt   7753644

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20240630.xsd EX-101.SCH 1139665
77 EXTRACTED XBRL INSTANCE DOCUMENT glue-20240630_htm.xml XML 1250153
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 241185966
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)